x
Filter:
Filters applied
- ISCT Publications
- Bertaina, AliceRemove Bertaina, Alice filter
- GvHDRemove GvHD filter
- CLPsRemove CLPs filter
- NRMRemove NRM filter
Publication Date
Please choose a date range between 2022 and 2022.
Keyword
- ADCC1
- Allogeneic hematopoietic stem cell transplant1
- Antibody dependent cellular cytotoxicity1
- CBT1
- Chronic GvHD Relapse Free Survival1
- Common lymphoid progenitors1
- CRFS1
- DFS1
- Disease Free Survival1
- Graft versus Host Disease1
- HCT1
- Hematopoietic progenitor cells1
- Hematopoietic Stem Cell Transplant1
- HPCSs1
- Immune Reconstitution1
- IR1
- Non-relapse mortality1
- OS1
- Overall Survival1
- Post-Transplant Cyclophosphamide1
- PTCy1
- T cell depleted1
ISCT Publications
1 Results
- ISCT Committee Paper
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes
CytotherapyVol. 24Issue 4p385–392Published in issue: April, 2022- Alice Bertaina
- Allistair Abraham
- Carmem Bonfim
- Sandra Cohen
- Duncan Purtill
- Annalisa Ruggeri
- and others
Cited in Scopus: 2Allogeneic stem cell transplantation is a potentially curative therapy for some malignant and non-malignant disease. There have been substantial advances since the approaches first introduced in the 1970s, and the development of approaches to transplant with HLA incompatible or alternative donors has improved access to transplant for those without a fully matched donor. However, success is still limited by morbidity and mortality from toxicity and imperfect disease control. Here we review our emerging understanding of how reconstitution of effective immunity after allogeneic transplant can protect from these events and improve outcomes.
